1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care
(
- Contribution to journal › Article
-
Mark
Metabolic pathways in immune senescence and inflammaging : Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology
(
- Contribution to journal › Article
-
Mark
Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma
(
- Contribution to journal › Article
- 2023
-
Mark
Eosinophils—from cradle to grave
(
- Contribution to journal › Article
-
Mark
Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma : An EAACI position paper
(
- Contribution to journal › Article
-
Mark
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both
(
- Contribution to journal › Article
-
Mark
Prescribing patterns of budesonide/formoterol maintenance and reliever therapy in patients with asthma in Sweden
(
- Contribution to journal › Letter
-
Mark
Efficacy of FP-025 : A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma
(
- Contribution to journal › Letter
- 2022
-
Mark
House dust mite sensitization and exposure affects bronchial epithelial anti-microbial response to viral stimuli in patients with asthma
(
- Contribution to journal › Article
-
Mark
Cysteinyl–leukotriene and prostaglandin pathways in bronchial versus alveolar lavage in allergic asthmatics
(
- Contribution to journal › Letter